{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T11:52:35Z","timestamp":1792324355602,"version":"4.4.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>We present a 74-year-old man with a history of very high-risk prostate cancer (Gleason score: 5+4 in 11 of 14 cores) who was referred for initial staging with <jats:sup>99m<\/jats:sup>Tc-HYNIC-PSMA. The scan was reported as miT<jats:sub>2m<\/jats:sub> N<jats:sub>2(REI, ROB)<\/jats:sub> M<jats:sub>1b(uni)<\/jats:sub> M<jats:sub>1c(skin?)<\/jats:sub>, PRIMARY score: 4, PSMA expression score: 1\u20133. We incidentally discovered increased uptake in the left skull region on whole-body images. Subsequent SPECT\/CT imaging localized this uptake to a subcutaneous nodule in the scalp, which pathologic analysis confirmed to be a neurofibroma. Several lesions of neurological origin may exhibit significant PSMA avidity, which is reviewed here.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005797","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T14:00:10Z","timestamp":1741010410000},"page":"e611-e613","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["99mTc-PSMA Uptake in Neurofibroma"],"prefix":"10.1097","volume":"50","author":[{"given":"Mohammad Hadi","family":"Samadi","sequence":"first","affiliation":[{"name":"Department of Dermatology, Nuclear Medicine Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Sahafi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nuclear Medicine Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haniye","family":"Elahifard","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nuclear Medicine Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Davoodi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Science, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2973-2251","authenticated-orcid":false,"given":"Emran","family":"Askari","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nuclear Medicine Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"R1-20250903","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcb.10661","article-title":"Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer","volume":"91","author":"Ghosh","year":"2004","journal-title":"J Cell Biochem"},{"key":"R2-20250903","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.nucmedbio.2016.08.006","article-title":"Radiolabeled enzyme inhibitors and binding agents targeting PSMA: effective theranostic tools for imaging and therapy of prostate cancer","volume":"43","author":"Pillai","year":"2016","journal-title":"Nucl Med Biol"},{"key":"R4-20250903","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/cne.903150208","article-title":"Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated \u03b1-linked acidic dipeptidase (NAALADase)","volume":"315","author":"Stauch Slusher","year":"1992","journal-title":"J Comp Neurol"},{"key":"R5-20250903","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res"},{"key":"R6-20250903","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1021\/jm000406m","article-title":"Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase)","volume":"44","author":"Kozikowski","year":"2001","journal-title":"J Med Chem"},{"key":"R7-20250903","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40644-020-00300-7","article-title":"Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings","volume":"20","author":"de Galiza Barbosa","year":"2020","journal-title":"Cancer Imaging"},{"key":"R8-20250903","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4274\/mirt.galenos.2021.97752","article-title":"Mild 68Ga PSMA-11 uptake in incidental pituitary adenoma","volume":"31","author":"Beyhan","year":"2022","journal-title":"Mol Imaging Radionucl Ther"},{"key":"R9-20250903","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1097\/RLU.0000000000002668","article-title":"18F-PSMA 1007 brain PET\/CT imaging in glioma recurrence","volume":"45","author":"Marafi","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R10-20250903","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/RLU.0000000000001451","article-title":"Diagnostic value of 68Ga PSMA-11 PET\/CT imaging of brain tumors\u2014preliminary analysis","volume":"42","author":"Sasikumar","year":"2017","journal-title":"Clin Nucl Med"},{"key":"R11-20250903","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/neuonc\/nox172","article-title":"The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?","volume":"19","author":"Unterrainer","year":"2017","journal-title":"Neuro Oncol"},{"key":"R12-20250903","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1097\/RLU.0000000000003347","article-title":"Oligodendroglioma in 68Ga-PSMA-11 and 18F-fluciclovine PET\/CT","volume":"46","author":"Pernthaler","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R13-20250903","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1097\/RLU.0000000000001769","article-title":"Prostate-specific membrane antigen\u2013targeted imaging with [18F] DCFPyL in high-grade gliomas","volume":"42","author":"Fragomeni","year":"2017","journal-title":"Clin Nucl Med"},{"key":"R14-20250903","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1097\/RLU.0000000000003117","article-title":"Incidentally detected 18F-PSMA uptake in glomus jugulare","volume":"45","author":"Zade","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R15-20250903","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00259-015-3235-y","article-title":"Intense PSMA-expression using 68 Ga-PSMA PET\/CT in a paravertebral schwannoma mimicking prostate cancer metastasis","volume":"43","author":"Rischpler","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R16-20250903","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1097\/RLU.0000000000005228","article-title":"Prostate-specific membrane antigen-avid neurofibroma mimicking cutaneous metastasis in metastatic castration-resistant prostate cancer on 18 F-PSMA-1007 PET\/CT","volume":"49","author":"Aggarwal","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R17-20250903","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5603\/nmr.97019","article-title":"Prostate-specific membrane antigen expression in intracranial lesions\u2014a review of the primary, metastatic, and nonneoplastic lesions","volume":"26","author":"Pe\u0142ka","year":"2023","journal-title":"Nucl Med Rev"},{"key":"R18-20250903","doi-asserted-by":"crossref","first-page":"e637","DOI":"10.1097\/RLU.0000000000004236","article-title":"Intense 68Ga-PSMA uptake in neurofibroma mimicking cutaneous metastases in a patient with prostate cancer","volume":"47","author":"Fenercio\u011flu","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R19-20250903","first-page":"1097","article-title":"Cutaneous and subcutaneous prostate-specific membrane antigen\u2013avid lesions","volume":"10","author":"Rafiei","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R20-20250903","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1212\/WNL.0000000000005792","article-title":"Cutaneous neurofibromas: current clinical and pathologic issues","volume":"91","author":"Ortonne","year":"2018","journal-title":"Neurology"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T21:00:43Z","timestamp":1756933243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005797","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"2024-11-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}